designed a bispecific antibody, anti-TRGV9/anti-CD123, that could simultaneously bind to the Vγ9 chain of Vγ9Vδ2 T cells and AML target antigen, CD123, then induce the recruitment and activation of Vγ9Vδ2 T cells to target AML blasts (141). This evidence concerns the gene TRGV9 and acute myeloid leukemia.